nephradin · Nephrology · Oral APRIL inhibitor to reduce proteinuria in adults with primary IgA nephropathy.
3 objectives · 2 on track, 1 off track
| Objective | Product | Owner | Status | Progress | Confidence |
|---|---|---|---|---|---|
| SO-NPH-01Build understanding of proteinuria reduction as a validated surrogate endpoint among nephrologists in US, DE and GB. | Nephrada | MLDr. Marcus Lindqvist | On track | 61% | Medium |
| SO-NPH-02Generate long-term eGFR slope evidence to support full approval and HTA submissions. | Nephrada | NPDr. Nikolai Petrov | Off track | 22% | Low |
| SO-NPH-03Establish patient-advocacy partnerships to inform patient-relevant outcome measures. | Nephrada | SLDr. Sophie Laurent | On track | 50% | Medium |
Initiative status mix per product; mean initiative progress alongside.
Active
3 initiatives · 43% mean progress
Status order: Completed · In progress · Planned · Not started · At risk · Blocked. Colours follow the status label shown in each legend.
Top 8 topics by insight count (duplicates excluded). Trend compares the last 60 days with the prior 60 days.
| Theme | Insights | Mean priority | Critical / High | Open high-priority | Trend (60d) |
|---|---|---|---|---|---|
| Treatment burden and fatigue | 5 | 62 | 60% | 1 | Flat 1 vs 1 |
| Steroid-sparing strategies | 4 | 61 | 25% | 1 | Flat 1 vs 1 |
| eGFR slope interpretation | 3 | 73 | 67% | 1 | Rising 2 vs 1 |
| Patient-reported outcomes | 3 | 62 | 67% | 1 | Flat 0 vs 0 |
| APRIL pathway mechanism | 1 | 66 | 100% | 0 | Falling 0 vs 1 |
| Proteinuria as surrogate endpoint | 1 | 57 | 0% | 0 | Flat 0 vs 0 |
1 initiatives at risk or blocked · 1 overdue tasks and actions
| Type | Item | Owner | Due | Status | Linked record |
|---|---|---|---|---|---|
| Task | T-1006Confirm FY2027 budget for GLOMERULAR-REG | MLDr. Marcus Lindqvist | 05 Sept 2026 (10 days ago) | Blocked | Initiative · INI-0202 |
| Initiative | INI-0202IgAN eGFR-slope registry (GLOMERULAR-REG) | NPDr. Nikolai Petrov | 31 Dec 2028 (in 838 days) | Blocked | Objective · SO-NPH-02 |
Submitted and reviewed engagements, FY2026 to date.
By stakeholder tier
Mean quality rating (1–5)
Mean 3.3 across 48 rated engagements: 1★ 0 · 2★ 2 · 3★ 26 · 4★ 17 · 5★ 3
Unique stakeholders
26
48 engagements
Tier 1 covered (6 mo)
11 / 13
85%
In person / virtual / phone
17 / 23 / 8
48% virtual
With ≥ 1 insight
16
33%
SLA compliance (MET-041) · target 92% · monthly, global scope
Jan 93.1% · Feb 92.4% · Mar 91.8% · Apr 92% · May 91.2% · Jun 90.6% · Jul 89.9% · Aug 89.4% · Sep 90.2%
The trend line is global; the counts below follow the selected scope.
Inquiries YTD
163
Open
4
Overdue
2
Breached (closed)
19
Escalated / safety
1 / 1
2 active publications · 2 of 2 planned submissions to date are submitted or beyond
Delayed milestones (0)
No publication milestones are past due.
2 projects · 0 active · 0 active at high risk
Budget review 1 · Rejected 1
By evidence gap
| Evidence gap | Projects | Active | Budget |
|---|---|---|---|
| Long-term eGFR slope data | 1 | 0 | $2.1M |
| Predictive biomarkers of response | 1 | 0 | $150k |
Weighted completion across scorecard dimensions. Grey dimensions carry no score; stale dimensions were last reviewed more than 30 days ago.
| Scorecard | Score | Dimensions (G / A / R / no data) | Warnings |
|---|---|---|---|
| Nephrada — pre-launch strategic scorecardExecutive summary · target 15 Mar 2027 · Dr. Marcus Lindqvist | 56% | 3 Green3 Amber2 Red0 No data | 10% of weight is stale |
FY2026 · planned $4.2M · committed $2.1M · actual $1.3M (32% consumed) · 0 lines at overrun risk
| Product | Planned | Committed | Actual | Consumed | Lines at risk |
|---|---|---|---|---|---|
| Nephrada | $4.2M | $2.1M | $1.3M | 32% | None |
2 teams · 2 over-allocated
Over-allocated teams
1 decision proposed or under review
NICE scientific advice (INS-0044) indicates eGFR slope data is required for positive recommendation.
Recommendation: Reallocate within NPH budget · Impact: Registry unblocked; reduced ASN 2027 presence · Approvers: Dr. Helen Okafor
Tenant-wide; not narrowed by product or region.
Open DQ issues
14
3 high · 7 medium · 4 low
Integrations degraded / failed
2
Veeva CRM (Degraded), Veeva Vault CTMS (Failed)
AI outputs pending review
3
INS-0061, INS-0060, RPT-Q3-EXEC
Metrics with DQ warnings
0
None
helixor-private-llm-2026.08 · generated 2026-09-15 06:00 UTC · scope: Nephrada · All regions · unapproved narratives are never distributed
Human review required
Strategic objectives
2 of 3 objectives are on track; 1 is at risk or off track (SO-NPH-02). Mean progress is 44% against a 70% year-end target.
Initiatives at risk
1 initiative is at risk or blocked: IgAN eGFR-slope registry (GLOMERULAR-REG) (blocked).
Sources:INI-0202
Escalated risks
1 risk is escalated to leadership. GLOMERULAR-REG not funded in FY2027, leaving no eGFR slope data for HTA submissions.
Sources:RSK-0003
Insights needing action
1 Critical or High insight has not yet been routed to an owning function. The most frequent open theme is "Treatment burden and fatigue".
Sources:INS-0081
Publication milestones
No publication milestones are past due.
Sources:none — derived from portfolio counts
Decisions needed
1 decision require leadership attention: Re-prioritise FY2027 budget to fund GLOMERULAR-REG.
Sources:DEC-0006